The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

**Member** | Consulting Fees/ Honoraria | Clinical Trials | Other Financial Benefit
---|---|---|---
**Primary Panel**
Satish R. Raj | Allergan, Lundbeck LLC, GE Healthcare | Bristol-Myers Squibb, Medtronic | None
Juan Camilo Guzman | None | None | None
Paula Harvey | None | None | None
Lawrence Richer | None | Janssen | None
Ronald Schondorf | None | None | None
Colette Seifer | None | None | None
Robert S. Sheldon | None | None | None
**Secondary Panel and International Members**
Hoshiar Abdollah | None | None | None
Carlos A. Morillo | Abbott Canada, Bayer, Boston Scientific, Daiichi-Sankyo, Medtronic, Merck, Pfizer, St. Jude Medical, Biotronik | Bayer, Boston Scientific, Daiichi-Sankyo, Medtronic, Servier | None
Shubhayan Sanatani | Audentes | None | None
Tara Sedlak | Amgen, Boehringer Ingelheim / Eli Lilly Alliance, Sanofi | None | None
Zaeem A. Siddiqi | None | GlaxoSmithKline, Pfizer | None
David Cannom | None | None | Medtronic
Nicholas Gall | None | None | None
Julia Newton | None | None | None
Win Shen | None | None | None